In summary, SGLT2 inhibition proved beneficial in adiposity and BP reduction in a hyperandrogenemic PCOS model; however, additional therapies may be needed to improve IR and renal injury. The gene discussed is SLC5A2; the disease is polycystic ovary syndrome.